SCHEMBL20520145

SCHEMBL20520145

Cc1cc(N2CC[C@H](NC(=O)O)C2)ncc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.39
AKT1 P31749 3/20 0.37
CA12 O43570 5/20 0.36
CA1 P00915 5/20 0.36
CA2 P00918 5/20 0.36
CA4 P22748 5/20 0.36
CA7 P43166 5/20 0.36
CA9 Q16790 5/20 0.36
SMO Q99835 4/20 0.36
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
SMPD3 Q9NY59 1/20 0.36
HRH4 Q9H3N8 1/20 0.35
KMT2A Q03164 1/20 0.35
KCNH2 Q12809 1/20 0.35
MCHR1 Q99705 1/20 0.35
ACKR3 P25106 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20520113 0.88 USP30 (0.47) USP30
SCHEMBL2183987 0.78 USP30 (0.48) USP30AKT1SMPD3ACKR3
SCHEMBL20524392 0.78 TRPV1 (0.44) AKT1CA12CA1CA2CA4
SCHEMBL20520106 0.78 TRPV1 (0.44) AKT1CA12CA1CA2CA4
SCHEMBL26097306 0.77 GRM1 (0.33) USP30
SCHEMBL13277370 0.75 USP30 (0.49) USP30SMO
SCHEMBL1485072 0.74 ALDH1A1 (0.50) KMT2A
SCHEMBL31575837 0.74 ALDH1A1 (0.50) KMT2A
SCHEMBL2180545 0.73 USP30 (0.45) USP30KMT2A
SCHEMBL17977006 0.73 CYP1A2 (0.40) HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3601284-B1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 HOFFMANN LA ROCHE (CH) 2023-12-27 EP disclosed
US-11034692-B1 Naphthyridines as inhibitors of HPK1 GENENTECH, INC. (US) 2021-06-15 US disclosed
US-10407424-B2 Naphthyridines as inhibitors of HPK1 GENENTECH, INC. (US) 2019-09-10 US disclosed
US-20180282328-A1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 GENENTECH, INC. (US) 2018-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10407424-B2 Naphthyridines as inhibitors of HPK1 NEK1, NEK5, NEK11 USP30 2072/4885AKT1 2988/4885CA12 4882/4885
US-20180282328-A1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 NEK1, NEK5, NEK11 USP30 2072/4885AKT1 2988/4885CA12 4882/4885
US-11034692-B1 Naphthyridines as inhibitors of HPK1 NEK1, NEK5, NEK11 USP30 2072/4885AKT1 2988/4885CA12 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.